Health Tech A Q&A with FDA’s Amy Abernethy on how the agency is grappling with digital health regulation By Megan Thielking @meggophone
January 8, 2020
STAT reporter Megan Thielking with FDA Principal Deputy Commissioner Amy Abernethy at CES 2020 in Las Vegas.
L AS VEGAS — The Food and Drug Administration announced this week it will hold a public meeting in late March to talk with digital health companies and other stakeholders about everything from privacy and data sharing to the standards of evidence needed to bring a new technology to the market.
The meeting is the latest in a string of steps the agency has taken as it grapples with how to regulate digital health products and tools that use artificial intelligence to help doctors decide how to treat patients.
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
GET STARTED Log In | Learn More What is it? STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day Online intelligence briefings Frequent opportunities to engage with veteran beat reporters and industry experts Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. GET STARTED
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology